Iktos and Facio Therapies Announce Collaboration to Use AI for FSHD Drug Design
Retrieved on:
Tuesday, May 11, 2021
b'Iktos, a company specialized in Artificial Intelligence for new drug design, and Facio Therapies, a drug discovery and development company focused on developing treatments for facioscapulohumeral dystrophy (FSHD), today announced entering a collaboration to apply Iktos\xe2\x80\x99s generative modelling artificial intelligence (AI) technology in one of Facio\xe2\x80\x99s drug discovery programs.
Key Points:
- b'Iktos, a company specialized in Artificial Intelligence for new drug design, and Facio Therapies, a drug discovery and development company focused on developing treatments for facioscapulohumeral dystrophy (FSHD), today announced entering a collaboration to apply Iktos\xe2\x80\x99s generative modelling artificial intelligence (AI) technology in one of Facio\xe2\x80\x99s drug discovery programs.
- This technology automatically designs virtual novel molecules with all of the characteristics of a successful drug molecule.
- Since inception, Facio has raised close to \xe2\x82\xac28M in equity funding from FSHD-affected families, their friends, FSHD foundations, and Facio\xe2\x80\x99s drug discovery partner, Evotec.
- Facio has been founded by business leaders from the FSHD community \xe2\x80\x93 Kees van der Graaf (Netherlands), Neil Camarta (Canada), and Bill Moss (Australia).\n'